Yale School of Medicine, New Haven, Connecticut, USA.
National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, People's Republic of China
Open Heart. 2021 Sep;8(2). doi: 10.1136/openhrt-2021-001666.
Access to acute cardiovascular care has improved and health services capacity has increased over the past decades. We assessed national changes in (1) patient characteristics, (2) in-hospital management and (3) patient outcomes among patients presenting with ST segment elevation myocardial infarction (STEMI) in 2011-2015 in China.
In a nationally representative sample of hospitals in China, we created two random cohorts of patients in 2011 and 2015 separately. We weighted our findings to estimate nationally representative numbers and assessed changes from 2011 to 2015. Data were abstracted from medical charts centrally using standardised definitions.
While the proportion of patients with STEMI among all patients with acute myocardial infarction decreased over time from 82.5% (95% CI 81.7 to 83.3) in 2011 to 68.5% (95% CI 67.7 to 69.3) in 2015 (p<0.0001), the weighted national estimate of patients with STEMI increased from 210 000 to 380 000. The rate of reperfusion eligibility among patients with STEMI decreased from 49.3% (95% CI 48.1 to 50.5) to 42.2% (95% CI 41.1 to 43.4) in 2015 (p<0.0001); ineligibility was principally driven by larger proportions with prehospital delay exceeding 12 hours (67.4%-76.7%, p<0.0001). Among eligible patients, the proportion receiving reperfusion therapies increased from 54% (95% CI 52.3 to 55.7) to 59.7% (95% CI 57.9 to 61.4) (p<0.0001). Crude and risk-adjusted rates of in-hospital death did not differ significantly between 2011 and 2015.
In this most recent nationally representative study of STEMI in China, the use of acute reperfusion increased, but no significant improvement occurred in outcomes. There is a need to continue efforts to prevent cardiovascular diseases, to monitor changes in in-hospital treatments and outcomes, and to reduce prehospital delay.
在过去几十年中,急性心血管治疗的可及性得到了改善,医疗服务能力也有所提高。我们评估了 2011-2015 年中国 ST 段抬高型心肌梗死(STEMI)患者的(1)患者特征、(2)院内管理和(3)患者结局的全国性变化。
在中国具有代表性的医院样本中,我们分别在 2011 年和 2015 年创建了两个随机队列的患者。我们对这些发现进行加权,以估计全国代表性的数量,并评估从 2011 年到 2015 年的变化。使用标准化定义,从病历中集中提取数据。
尽管 STEMI 患者在急性心肌梗死患者中的比例随时间推移从 2011 年的 82.5%(95%CI 81.7-83.3)降至 2015 年的 68.5%(95%CI 67.7-69.3)(p<0.0001),但 STEMI 患者的全国估计人数从 210000 人增加到 380000 人。STEMI 患者的再灌注适宜率从 49.3%(95%CI 48.1-50.5)降至 2015 年的 42.2%(95%CI 41.1-43.4)(p<0.0001);不适合的主要原因是院前延误超过 12 小时的比例较大(67.4%-76.7%,p<0.0001)。在适宜的患者中,接受再灌注治疗的比例从 54%(95%CI 52.3-55.7)增加到 59.7%(95%CI 57.9-61.4)(p<0.0001)。2011 年和 2015 年之间,院内死亡率的粗死亡率和风险调整后率没有显著差异。
在这项针对中国最新的 STEMI 全国代表性研究中,急性再灌注的使用增加了,但结局没有明显改善。需要继续努力预防心血管疾病,监测院内治疗和结局的变化,并减少院前延误。